S-1: Lenz Therapeutics Files for Resale of Common Stock After Graphite Bio Merger

Lenz Therapeutics registers for the resale of 1,297,411 shares of common stock issued in a PIPE financing following its merger with Graphite Bio.

Summary

• Lenz Therapeutics, Inc., a late-stage biopharmaceutical company, has filed a registration statement for the resale of 1,297,411 shares of its common stock.
• These shares were issued in a private placement (PIPE financing) concurrent with the completion of the merger between Lenz Therapeutics and Graphite Bio, Inc.
• The company is focused on developing and commercializing therapies for vision improvement, with an initial focus on presbyopia.
• Lenz's product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops for treating presbyopia.
• Top-line results from Phase 3 clinical trials for LNZ100 and LNZ101 are expected in April 2024, with a potential NDA submission to the FDA in mid-2024.
• If approved, the company targets a commercial launch in the second half of 2025.
• The company estimates the U.S. market opportunity for a presbyopia eye drop to be in excess of $3 billion.
• The company has assembled a commercial team and is building a commercial strategy in the United States to be launch-ready upon expected timing of FDA approval.
• The company's product candidates have patent protection until 2039.
• The company believes that it could be the first FDA-approved aceclidine-based product and would then be eligible for five years of NCE exclusivity in the United States.
• The company had $65.8 million of cash, cash equivalents and short-term investments as of December 31, 2023.
• The company believes that its existing cash, cash equivalents and short-term investments, together with the proceeds from the merger and the Graphite private placement will allow the company to continue to build infrastructure and commercialize its lead product candidate, subject to successful completion of the ongoing Phase 3 trials, the NDA submission and FDA approval.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the potential of Lenz Therapeutics and the risks associated with its business. The positive Phase 3 trial results and market opportunity are encouraging, but the company's reliance on a single product and the competitive landscape temper the overall sentiment.

Positives

• Lenz Therapeutics is in late-stage clinical development with Phase 3 results expected soon.
• The company has a strong intellectual property position with patents extending to 2039.
• The company has a large estimated market opportunity of over $3 billion in the U.S.
• The company has a commercial launch target date in the second half of 2025.
• The company has assembled a commercial team and is building a commercial strategy in the United States to be launch-ready upon expected timing of FDA approval.

Negatives

• The company has incurred net losses in each year since inception and expects to continue to incur significant expenses and operating losses for the foreseeable future.
• The company's business depends entirely on the development and commercialization of LNZ100 or LNZ101, and it does not have additional product candidates in its current development pipeline.
• Clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome.
• Even if LNZ100, LNZ101 or any other product candidate receives marketing approval, they may fail to achieve market acceptance by ECPs and patients, and the market opportunity for these products, if approved, may be smaller than the company estimates.

Risks

• The company's business depends entirely on the development and commercialization of LNZ100 or LNZ101.
• Clinical trial outcomes are uncertain, and results may not satisfy regulatory requirements.
• The company faces significant competition from other pharmaceutical companies and existing treatments.
• The company relies on third parties for clinical trials and manufacturing, which could lead to delays or insufficient quantities of product candidates.
• The company may need to raise additional financing in the future to fund its operations, which may not be available on favorable terms or at all.
• The market price of the company's common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.

Future Outlook

The company plans to submit an NDA to the FDA in mid-2024, targeting a commercial launch in the second half of 2025, pending successful completion of Phase 3 trials and FDA approval.

Industry Context

The document highlights the competitive landscape in the presbyopia treatment market, noting the presence of companies like AbbVie, Bausch & Lomb, and others developing pharmaceutical therapies. It also acknowledges the existing market for over-the-counter reading glasses and prescription lenses.

Comparison to Industry Standards

• The document mentions AbbVie's Vuity as the only currently approved pharmaceutical treatment for presbyopia, noting its initial strong launch but subsequent limitations in efficacy and duration.
• The document references independent, peer-reviewed, academic studies conducted by third parties and summarized by W. Neil Charman in a published editorial that have shown that pupil diameter is highly correlated with the depth of focus and that reducing pupil diameters below 2 mm is correlated with a dramatic increase in depth of focus.
• The document references an independent, peer-reviewed, academic study of near vision improvement conducted by a third party across a variety of lighting conditions, pupil diameters below 2 mm were correlated with twoto five-lines or greater improvement in near visual acuity.

Legal Proceedings

• The document mentions that one complaint has been filed in the United States District Court for the Northern District of California and one complaint has been filed in the United States District Court for the District of Delaware generally alleging that the definitive proxy statement/prospectus misrepresents and/or omits certain purportedly material information relating to LENZs financial projections, the analyses performed by the financial advisor to Graphites Board of Directors in connection with the Merger, potential conflicts of interest of the financial advisor to Graphites Board of Directors, potential conflicts of interest of Graphites officers, and Graphites liquidation analysis.
• The document mentions that the Complaints assert violations of Section 14(a) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and Rule 14a-9 promulgated thereunder against all defendants (Graphite, its Board of Directors and certain officers) and violations of Section 20(a) of the Exchange Act against Graphites directors and officers.
• The document mentions that the Complaints seek orders enjoining the proposed Merger, or in the event that the proposed Merger is consummated, an order rescinding the Merger or awarding rescissory damages, as well as costs, including attorneys and experts fees.
• The document mentions that Graphite also received twelve additional demand letters by purported Graphite stockholders from December 14, 2023 to March 20, 2024 seeking additional disclosures in the Proxy Statement/Prospectus (the Demands).

Related Party Transactions

• Dr. Porteus, a director and stockholder of Graphite, is the founder and chief executive officer of Kamau.
• Samsara BioCapital and funds affiliated with Versant Ventures, both of which are greater than 5% stockholders of Graphite, are related to Maro Bio Inc.
• Zach Scheiner, a member of the LENZ board of directors, is an affiliate of RA Capital.
• Chris Dimitropoulos, a member of LENZ OpCos board of directors until immediately prior to the Effective Time, is an affiliate of Alpha Wave Ventures II, LP.
• Stefan Larson, a member of LENZ OpCos board of directors until immediately prior to the Effective Time, is a partner at Sectoral Asset Management Inc.
• James McCollum, a member of the LENZ board of directors, is the trustee of the McCollum Living Trust.

Stakeholder Impact

• Shareholders: The document outlines the potential for increased value through the development and commercialization of presbyopia treatments, but also highlights risks that could negatively impact the share price.
• Employees: The document mentions the company's commitment to attracting and retaining talent, as well as the implementation of restructuring plans that resulted in workforce reductions.
• Customers: The document focuses on developing innovative therapies to improve vision and address the needs of presbyopes.
• Creditors: The document discusses the company's liquidity and capital resources, which could impact its ability to meet its financial obligations.

Next Steps

• Announce top-line results from Phase 3 clinical trials (CLARITY) in April 2024.
• Submit a New Drug Application (NDA) to the FDA for LNZ100 and/or LNZ101 in mid-2024.
• Evaluate Phase 3 data and FDA feedback to select the product candidate for commercialization.
• Commercialize LNZ100 or LNZ101, with a target launch date in the second half of 2025, pending FDA approval.

Key Dates

Keywords

Lenz Therapeutics, presbyopia, LNZ100, LNZ101, PIPE financing, Graphite Bio, clinical trials, FDA, pharmaceutical, ophthalmology, aceclidine, brimonidine